Contents

Search

PD-L1 in specimen

Indications: - predictive biomarker for checkpoint immunotherapy in NSCLC [1] & other malignancies [2] Procedure: - PD-L1 testing by immunohistochemistry

Related

programmed cell death 1 ligand 1; PD-L1; PDCD1 ligand 1; programmed death ligand 1; B7 homolog 1; B7-H1; CD274 (CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1)

Specific

PD-L1 in blood PD-L1 in tissue

General

protein measurement

References

  1. Fuerst ML with critique by Bowman AI Blood Test Appears to Enable Immunotherapy Selection, Monitoring - Allows repeat testing, timely monitoring, and has potential to improve adherence to NCCN guidelines. MedPage Today. ASCO Reading Room 05.31.2018 https://www.medpagetoday.com/reading-room/asco/immunotherapy/73187
  2. Bajorin DF, Witjes JA, Gschwend JE Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 2021; 384:2102-2114. June 3 PMID: 34077643 https://www.nejm.org/doi/full/10.1056/NEJMoa2034442
  3. ARUP Consult: PD-L1 Testing The Physician's Guide to Laboratory Test Selection & Interpretation https://arupconsult.com/content/pd-l1-testing - PD-L1 Testing Algorithm https://arupconsult.com/algorithm/pd-l1-testing-algorithm